July 2024

Contents

Editorial

• i-Base printed resources: please order now while stocks last

Conference reports

• AIDS 2024: Lenacapavir as PrEP is “beyond wonderful” but PURPOSE 1 study tells us so much more 

• Lenacapavir could be produced for $40 a year: 1000-fold lower than current US price for treating MDR HIV

• AIDS 2024: Introduction to AIDS 2024

• UNAIDS report: The urgency of now – AIDS at a crossroads.

• New community call to challenge social settings that drive HIV-related stigma

• HIV research to watch out for at the AIDS 2024 conference

Antiretrovirals

• HIV pipeline: global overview for people in LMICs

Treatment access

• CHAI six-monthly market report (July 2024)

Guidelines

• Low efficacy and high price of dapivirine ring: not included as PrEP in South African guidelines

• Updated WHO guidelines for HIV PEP (July 2024)

• New US screening guidelines to reduce risk of anal cancer in people living with HIV

Side effects

• Semaglutide in people with HIV: reduces both central and peripheral fat worsening lipoatrophy